These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 3498104)

  • 1. [Cancer therapy with interleukin 2 and activated killer cell--a review].
    Jondal M; Ullberg M
    Lakartidningen; 1987 Apr; 84(18):1553-7. PubMed ID: 3498104
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin-2, killer cells and cancer therapy: an overview.
    Parkinson DR; Lotzová E
    Nat Immun Cell Growth Regul; 1990; 9(4):237-41. PubMed ID: 2215512
    [No Abstract]   [Full Text] [Related]  

  • 3. Natural killer cells and tumor immunity: 1987.
    Hiserodt JC; Herberman RB
    Year Immunol; 1989; 4():201-7. PubMed ID: 2648702
    [No Abstract]   [Full Text] [Related]  

  • 4. [Our experience with lymphocytes activated against cancer: CTL cells].
    Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
    G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
    Melief CJ
    Adv Cancer Res; 1992; 58():143-75. PubMed ID: 1532109
    [No Abstract]   [Full Text] [Related]  

  • 6. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
    Sondel PM; Hank JA; Kohler PC; Chen BP; Sosman J
    Prog Clin Biol Res; 1989; 288():151-60. PubMed ID: 2654949
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biological immunomodulators in the treatment of cancer].
    Bello C; Richard C; Hermosa V; Iriondo A; Muruzábal MJ; Pérez Encinas M; Zubizarreta A
    Sangre (Barc); 1988 Apr; 33(2):132-43. PubMed ID: 2456623
    [No Abstract]   [Full Text] [Related]  

  • 8. [Interleukin 2, killer cells and cancer].
    Timonen T
    Duodecim; 1988; 104(9):685-9. PubMed ID: 3049038
    [No Abstract]   [Full Text] [Related]  

  • 9. Interleukin-2 and lymphokine-activated killer cell therapy for gastrointestinal cancer.
    Guillou P
    Acta Chir Scand Suppl; 1989; 549():26-30. PubMed ID: 2784604
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacologic studies with recombinant human interleukin 2].
    Mayer P; Hodgin L
    Zentralbl Veterinarmed A; 1987 Dec; 34(10):755-65. PubMed ID: 3124399
    [No Abstract]   [Full Text] [Related]  

  • 11. Lymphokine-activated killer cells are generated before classical cytotoxic T lymphocytes after bone marrow transplantation in mice.
    Merluzzi VJ; Savage DM; Smith MD; Last-Barney K; Mertelsmann R; Moore MA; Welte K
    J Immunol; 1985 Sep; 135(3):1702-6. PubMed ID: 3894518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cancer immunotherapy: new approaches].
    Blay JY; Thomachot MC; Alberti L; Bachelot T; Voorzanger-Rousselot N; Puisieux I; Odin L; Ménétrier-Caux C
    Bull Cancer; 2000 Jan; 87(1):97-106. PubMed ID: 10673638
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of cancer with lymphokine-activated killer cells and interleukin-2.
    N Engl J Med; 1987 Oct; 317(15):961-3. PubMed ID: 3498120
    [No Abstract]   [Full Text] [Related]  

  • 14. [LAK cells and cancer].
    Taguchi T; Kimoto Y
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summary: potential of interleukin-2 for the therapy of cancer.
    Herberman RB
    J Biol Response Mod; 1984 Oct; 3(5):527-32. PubMed ID: 6389778
    [No Abstract]   [Full Text] [Related]  

  • 16. [Adoptive immunotherapy of malignant diseases using normal allogeneic LAK cells].
    Kimoto Y; Tanji Y; Tanaka T; Taguchi T
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1884-9. PubMed ID: 3496050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
    Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer.
    Whiteside TL; Chikamatsu K; Nagashima S; Okada K
    Anticancer Res; 1996; 16(4C):2357-64. PubMed ID: 8816835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.